查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1718265

核酸治疗 CDMO 市场（按治疗类型、服务类型、治疗应用和最终用户划分）—2025 年至 2030 年全球预测

Nucleic Acid Therapeutics CDMO Market by Therapeutics Type, Service Type, Therapeutic Applications, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2024年核酸治疗CDMO市场价值将达107.7亿美元，2025年将成长至120亿美元，复合年增长率为11.42%，到2030年将达到206.2亿美元。

主要市场统计数据
基准年2024年 107.7亿美元
预计2025年 120亿美元
预测年份 2030 206.2亿美元
复合年增长率（%） 11.42%

核酸疗法已成为重新定义现代医学的革命性方法。受託製造厂商(CDMO) 格局正在快速发展，以满足先进基因疗法和突破性医疗治疗设定的严格标准。最近的科学突破，加上不断扩大的法律规范，迫切需要创新和专业製造服务。强大的分析测试、精确的品管和客製自订製造解决方案的整合使这些组织能够支持基于 DNA 和 RNA 的治疗方法的复杂需求。

此外，遗传疾病、感染疾病和肿瘤学领域治疗应用的不断扩大表明，研究突破与临床需求之间存在着密切的交集。这个市场故事不仅强调了学术界、生物技术和製药产业之间合作伙伴关係的重要性，也强调了调整传统製造方法以适应新型生物治疗分子的重要性。随着市场基本面的变化，决策者正在考虑利用新技术和优化生产效率的机会。

核酸疗法的发展既带来了挑战，也带来了巨大的机会。随着对精确度、可扩展性和快速创新的需求不断增长，CDMO 在科学创造力和製造专业知识的融合中占据着独特的地位。这项全面的研究对市场区隔、区域动态和主要产业参与者的影响提供了深入的见解，提供了支持策略决策的权威概述。

核酸治疗领域变革

在科学创新、数位转型和不断变化的法规环境的推动下，核酸治疗市场正在发生巨大变化。传统的药物开发模式正在被敏捷製造流程和整合技术解决方案重新定义。 RNA 和 DNA 疗法研发步伐的加快需要能够提供高效可靠产品的新製造方法。

相关人员正在见证从传统小分子製造到更细緻的生物製造策略的转变。这项转变将以采用先进的分析平台和增强的製程控制系统为标誌，以确保精确的品管。此外，涉及基因编辑和传讯RNA技术的治疗方法的快速扩展正在推动对灵活、强大的製造伙伴关係关係的需求，这些合作伙伴关係可以在保持法规遵从性的同时快速扩大生产规模。

同时，市场正在拥抱研究和生产方法的数位转型。云端基础的数据分析和即时监控正在整合到生产工作流程中，从而实现主动调整和持续改进。这些变化大大缩短了上市时间，并克服了生技药品製造中固有的一些传统瓶颈，将该领域推向了新的高度。

竞争因素正在重新定义竞争格局。这种转变不仅是技术上的，也是文化上的，需要重新关注协作、风险管理和对尖端製造基础设施的策略性投资。

市场区隔洞察推动市场创新

以细分市场分析核酸治疗市场，可以发现其多方面的结构，可满足不同的需求和专业知识。市场按治疗剂类型细分，涵盖 DNA 和 RNA 模式。虽然 DNA 疗法传统上具有稳定性和良好的记录，但 RNA 疗法具有快速的开发週期和可调节的基因表现，并不断突破界限。这两条路径代表了既定协议和新创新之间的策略平衡。

按服务类型细分进一步阐明了分析测试和品管、製造、包装和分销以及流程开发和优化等领域。每个服务类别在确保治疗不仅有效且可靠方面发挥着至关重要的作用。随着监管机构实施更严格的标准，分析测试和品管变得越来越重要，并且透过精密工程和自动化的整合来增强製造能力。包装和分销，加上工艺开发，提供了从实验室创新到患者交付的无缝连续性。

在考虑治疗应用时，可以从各种临床学科中得出见解，包括遗传学、感染疾病、神经病学、肿瘤学和罕见疾病。每个应用领域都有其自身的挑战和机会，推动我们的研究和开发策略。例如，肿瘤学和神经系统疾病治疗模式的不断发展促使人们重新审视传统的药物传递系统，并鼓励创造新的、有针对性的干预措施。

此外，按学术和研究机构、生物技术公司和製药公司的最终用户细分，显示核酸疗法被广泛采用。学术界推动基础研究，而生物技术则迅速将研究发现转化为临床应用。同时，製药公司正在将这些创新推向全球市场，以确保在日益激烈的竞争环境中获得产品并实现永续成长。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 全球遗传疾病的盛行率不断上升
      • 个人化医疗和标靶基因治疗的需求不断增加
      • 扩大製药和生技领域的研发活动
    • 限制因素
      • 严守核酸药物生产相关规定
    • 机会
      • 利用先进的核酸稳定技术和分析测试平台在 CDMO 环境中实现先进的治疗应用
      • 持续开发基于 mRNA 的疫苗和疗法
    • 任务
      • 核酸药物研发专业人才短缺
  • 市场区隔分析
    • 服务类型：人们对纯度和效力的分析测试以及品管服务的兴趣日益浓厚
    • 最终用户：核酸治疗CDMO在学术研究机构的应用不断扩大
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

6. 核酸治疗 CDMO 市场（依治疗类型）

  • DNA治疗公司
  • RNA治疗学

第七章 核酸治疗 CDMO 市场（依服务类型）

  • 分析测试和品管
  • 製造业
  • 包装和运输
  • 製程开发与最佳化

8. 核酸治疗CDMO市场治疗应用

  • 遗传性疾病
  • 感染疾病
  • 神经系统疾病
  • 肿瘤学
  • 罕见疾病

第九章 核酸治疗 CDMO 市场（依最终使用者）

  • 学术研究所
  • 生技公司
  • 製药公司

10.美洲核酸治疗CDMO市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

11. 亚太地区核酸治疗CDMO市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

12. 欧洲、中东和非洲核酸治疗 CDMO 市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • AGC Biologics Inc.
  • Agilent Technologies, Inc.
  • Ajinomoto Bio-Pharma Services
  • Almac Group Ltd.
  • Biomay AG
  • BioSpring GmbH
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • CordenPharma International GmbH
  • Creative Biogene
  • Danaher Corporation
  • Eurofins Scientific SE
  • Evonik Industries AG
  • GenScript Biotech Corporation
  • Lonza Group Ltd.
  • Polypeptide Group AG
  • Recipharm AB
  • Rentschler Biopharma SE
  • Samsung Biologics
  • The Scripps Research Institute
  • Touchlight Group
  • Univercells Group
  • WuXi AppTec Co., Ltd.
Product Code: MRR-CA7E340319CD

The Nucleic Acid Therapeutics CDMO Market was valued at USD 10.77 billion in 2024 and is projected to grow to USD 12.00 billion in 2025, with a CAGR of 11.42%, reaching USD 20.62 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 10.77 billion
Estimated Year [2025] USD 12.00 billion
Forecast Year [2030] USD 20.62 billion
CAGR (%) 11.42%

Nucleic acid therapeutics have emerged as transformative modalities redefining modern medicine. The landscape of contract development and manufacturing organizations (CDMOs) is rapidly evolving to meet the rigorous standards set by advanced gene therapies and revolutionary treatments. Recent scientific breakthroughs, combined with an expanding regulatory framework, have driven both innovation and an urgent need for specialized manufacturing services. The integration of robust analytical testing, precision quality control, and custom manufacturing solutions has enabled these organizations to support the complex demands of DNA- and RNA-based therapies.

Furthermore, the expansion of therapeutic applications across genetic disorders, infectious diseases, and oncology demonstrates a keen intersection between research breakthroughs and clinical needs. This market narrative not only highlights the importance of collaborative partnerships across academia, biotechnology, and pharmaceutical industries but also underscores the significance of adapting traditional manufacturing methodologies to handle novel biotherapeutic molecules. As market fundamentals shift, decision-makers are examining opportunities to leverage new technologies and optimize production efficiency.

The evolution of nucleic acid therapeutics presents both challenges and substantial opportunities. With increasing demands for precision, scalability, and rapid innovation, CDMOs are positioned uniquely at the confluence of scientific creativity and production expertise. This comprehensive exploration sets the stage for in-depth insights into market segmentation, regional dynamics, and the influence of key industry players, providing an authoritative overview structured to support strategic decision-making.

Transformative Shifts Reshaping the Nucleic Acid Therapeutics Landscape

The nucleic acid therapeutics market is experiencing dramatic shifts driven by scientific innovation, digital transformation, and evolving regulatory environments. Traditional drug development paradigms are being redefined by agile manufacturing processes and integrated technology solutions. The accelerating pace of RNA and DNA therapeutic discovery has necessitated new production methodologies that can deliver products with both high efficacy and reliability.

Stakeholders are witnessing a transition from conventional small molecule production to more nuanced biological manufacturing strategies. This transformation is characterized by the adoption of advanced analytical platforms and enhanced process control systems that ensure precise quality control. Moreover, the rapid expansion of therapeutic modalities, including gene editing and messenger RNA technologies, has driven demand for agile and robust manufacturing partnerships capable of scaling production swiftly while maintaining regulatory compliance.

Simultaneously, the marketplace is embracing the digital transformation of research and production methods. Cloud-based data analytics and real-time monitoring are being integrated into production workflows, enabling proactive adjustments and continuous improvement. These changes are propelling the sector to greater heights by significantly reducing time-to-market and overcoming some of the traditional bottlenecks inherent in biologics manufacturing.

Collectively, these factors are redefining competitive strategies across the landscape. The shift is not simply technological but cultural, demanding a renewed focus on collaboration, risk management, and strategic investment in state-of-the-art manufacturing infrastructure.

Key Segmentation Insights Driving Market Innovation

The segmented analysis of the nucleic acid therapeutics market reveals a multifaceted structure that caters to diverse needs and specialized capabilities. The market is dichotomized by therapeutics type, studying both DNA and RNA modalities. DNA therapeutics have traditionally provided stability and a proven track record, while RNA therapeutics continue to push boundaries, offering rapid development cycles and tunable gene expression. This dual pathway represents a strategic balance between established protocols and emerging innovations.

Service type segmentation further illuminates areas such as analytical testing and quality control, manufacturing, packaging and distribution, and process development and optimization. Each service category plays a pivotal role in ensuring therapies are not only effective but also reliably delivered. Analytical testing and quality control have become increasingly critical as regulatory bodies enforce stricter criteria, while manufacturing capabilities are being enhanced by the integration of precision engineering and automation. Packaging and distribution, coupled with process development, provide a seamless continuum from laboratory innovation to patient delivery.

When examining therapeutic applications, insights are drawn from various clinical sectors including genetic disorders, infectious diseases, neurological disorders, oncology, and rare disorders. Each application area carries unique challenges and opportunities that drive tailored research and development strategies. The evolution of treatment paradigms in oncology and neurological disorders, for instance, is prompting a re-examination of traditional drug delivery systems and inspiring the creation of novel, targeted interventions.

Moreover, the segment based on end users-spanning academic and research institutes, biotechnology firms, and pharmaceutical companies-exemplifies the extensive reach of nucleic acid therapies. The academic realm propels foundational research, while the biotechnology sector rapidly translates discoveries into clinical applications. Pharmaceutical companies, on the other hand, bring these innovations to a global market, ensuring accessibility and sustained growth in an increasingly competitive environment.

Based on Therapeutics Type, market is studied across DNA Therapeutics and RNA Therapeutics.

Based on Service Type, market is studied across Analytical Testing & Quality Control, Manufacturing, Packaging & Distribution, and Process Development & Optimization.

Based on Therapeutic Applications, market is studied across Genetic Disorders, Infectious Diseases, Neurological Disorders, Oncology, and Rare Disorders.

Based on End User, market is studied across Academic & Research Institutes, Biotechnology Firms, and Pharmaceutical Companies.

Key Regional Insights Across Global Markets

The global perspective of nucleic acid therapeutics uncovers significant regional variations that highlight both unique opportunities and sector-specific challenges. In the Americas, advanced research infrastructures and a robust funding environment have fostered an ecosystem where innovation thrives alongside regulatory excellence. This region continues to lead in terms of clinical trials and state-of-the-art manufacturing facilities, making it a hotspot for next-generation therapeutic discovery and production.

Across Europe, the Middle East, and Africa, there is a pronounced emphasis on harmonizing regulatory standards while fostering an environment conducive to public-private partnerships. European markets, in particular, are noted for stringent compliance and quality benchmarks, which drive industry standards upward. The Middle East and Africa are witnessing increasing investments in biotechnological research, motivated by a growing need to address regional health challenges and tap into emerging talent pools. This diverse region articulates a unique blend of legacy expertise and innovative agility.

In Asia-Pacific, rapid economic development and substantial investments in research and development are redefining the landscape. The region benefits from a mix of established industrial bases and nimble start-ups, which together contribute to a competitive production and innovation environment. The surge in regulatory reforms is further catalyzing innovation, ensuring that manufacturing processes keep pace with global benchmarks. This dynamic region not only supports large-scale clinical development but also serves as a critical hub for supply chain optimization and operational excellence across the nucleic acid therapeutics market.

These region-specific insights reinforce the view that a one-size-fits-all approach is untenable. Instead, tailored strategies that account for local market dynamics, resource availability, and regulatory environments are essential for tapping the diverse global potential of nucleic acid therapeutics.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Leading the Charge in Therapeutics Innovation

The competitive landscape is defined by a cadre of leading companies whose innovative approaches are setting new standards in the nucleic acid therapeutics market. Firms such as AGC Biologics Inc. and Agilent Technologies, Inc. are recognized for their commitment to integrating advanced analytics with meticulous quality control processes. Ajinomoto Bio-Pharma Services and Almac Group Ltd. have carved out reputations for excellence in manufacturing and process optimization, consistently delivering reliable solutions that meet rigorous industry standards.

Equally influential are organizations like Biomay AG and BioSpring GmbH, which have leveraged cutting-edge technologies to optimize both packaging and distribution channels. Catalent, Inc. and Charles River Laboratories International, Inc. have been instrumental in refining manufacturing protocols and streamlining analytical testing methodologies that enhance overall product reliability. Industry leaders such as CordenPharma International GmbH and Creative Biogene exemplify the ability to balance high-volume production with precision customization.

Danaher Corporation and Eurofins Scientific SE further underscore the critical role of innovative testing and quality assurance procedures, while companies including Evonik Industries AG and GenScript Biotech Corporation have accelerated process development and optimization. Lonza Group Ltd. and Polypeptide Group AG stand out for their scalable manufacturing solutions, ensuring seamless transitions from bench to market. Other key players, including Recipharm AB and Rentschler Biopharma SE, have continued to drive efficiency and innovation in both traditional and next-generation therapeutic production.

Samsung Biologics and The Scripps Research Institute illustrate the vital interconnectedness of research and manufacturing, a trait shared by Touchlight Group, Univercells Group, and WuXi AppTec Co., Ltd. Their combined efforts are not only redefining production paradigms but are also instrumental in pushing the boundaries of what is scientifically and commercially possible in the realm of nucleic acid therapeutics.

The report delves into recent significant developments in the Nucleic Acid Therapeutics CDMO Market, highlighting leading vendors and their innovative profiles. These include AGC Biologics Inc., Agilent Technologies, Inc., Ajinomoto Bio-Pharma Services, Almac Group Ltd., Biomay AG, BioSpring GmbH, Catalent, Inc., Charles River Laboratories International, Inc., CordenPharma International GmbH, Creative Biogene, Danaher Corporation, Eurofins Scientific SE, Evonik Industries AG, GenScript Biotech Corporation, Lonza Group Ltd., Polypeptide Group AG, Recipharm AB, Rentschler Biopharma SE, Samsung Biologics, The Scripps Research Institute, Touchlight Group, Univercells Group, and WuXi AppTec Co., Ltd.. Actionable Recommendations for Industry Leaders in Therapeutics

Industry leaders must adopt a multidimensional strategy to navigate the shifting landscape of nucleic acid therapeutics effectively. It is crucial to invest in state-of-the-art manufacturing infrastructure, ensuring seamless integration of digital analytics with process automation. Firms should proactively engage with regulatory bodies to remain ahead of compliance curves, thus securing a competitive edge in innovation and market penetration.

Collaboration remains a powerful tool in this sector. Establishing strategic partnerships with research institutions, biotechnology innovators, and global pharmaceutical companies can help accelerate product development and broaden market reach. Emphasis on robust risk management strategies, coupled with the adoption of advanced manufacturing platforms, will serve as catalysts for operational excellence. Leaders in the field are encouraged to leverage emerging technologies that promise enhanced scalability and faster time-to-market, aligning production capabilities with the rapidly evolving clinical demands.

Lastly, maintaining an agile mindset is critical as market dynamics continue to evolve. Organizations that invest in continual improvement and foster an environment of cross-disciplinary innovation will be best positioned to capitalize on the emerging opportunities within this space.

Conclusion: Embracing Change in Nucleic Acid Therapeutics

In conclusion, the advancement of nucleic acid therapeutics represents a significant leap forward in modern medicine. The market is witnessing an era of transformative change, driven by innovative scientific breakthroughs, strategic segmentation insights, and a competitive ecosystem dominated by leading industry players. The evolving landscape requires a nuanced understanding of the interplay between technology, regulation, and market dynamics.

This comprehensive analysis underscores the importance of adopting forward-thinking strategies and leveraging global insights to build resilient and efficient production pipelines. The future of nucleic acid therapeutics lies in the hands of those who not only embrace change but also proactively drive its evolution through innovation, collaboration, and strategic investment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of genetic disorders globally
      • 5.1.1.2. Rising demand for personalized medicine and targeted gene therapies
      • 5.1.1.3. Expansion of research and development activities in pharmaceutical and biotechnology sectors
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent regulatory compliance in production of nucleic acid therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Leveraging advanced nucleic acid stabilization techniques and analytical testing platforms for advanced therapeutic applications in CDMO settings
      • 5.1.3.2. Ongoing development of mRNA-based vaccines and therapeutics
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of skilled professionals specialized in nucleic acid therapeutics development
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Service Type: Increasing preference for analytical testing & quality control services for their purity, and potency
    • 5.2.2. End User: Expanding utilization of nucleic acid therapeutics CDMO in academic & research institutes
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Nucleic Acid Therapeutics CDMO Market, by Therapeutics Type

  • 6.1. Introduction
  • 6.2. DNA Therapeutics
  • 6.3. RNA Therapeutics

7. Nucleic Acid Therapeutics CDMO Market, by Service Type

  • 7.1. Introduction
  • 7.2. Analytical Testing & Quality Control
  • 7.3. Manufacturing
  • 7.4. Packaging & Distribution
  • 7.5. Process Development & Optimization

8. Nucleic Acid Therapeutics CDMO Market, by Therapeutic Applications

  • 8.1. Introduction
  • 8.2. Genetic Disorders
  • 8.3. Infectious Diseases
  • 8.4. Neurological Disorders
  • 8.5. Oncology
  • 8.6. Rare Disorders

9. Nucleic Acid Therapeutics CDMO Market, by End User

  • 9.1. Introduction
  • 9.2. Academic & Research Institutes
  • 9.3. Biotechnology Firms
  • 9.4. Pharmaceutical Companies

10. Americas Nucleic Acid Therapeutics CDMO Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Nucleic Acid Therapeutics CDMO Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Nucleic Acid Therapeutics CDMO Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Maravai LifeSciences broadens its nucleic acid therapeutics pipeline by acquiring Officinae Bio's DNA and RNA business
    • 13.3.2. GSK forges strategic licensing deal with Touchlight to access advanced doggybone DNA technology
    • 13.3.3. FUJIFILM Toyama Chemical and Synplogen Forge Alliance to Enhance mRNA Therapeutics Production
    • 13.3.4. Exothera Launches Advanced RNA Therapeutics Platform 'Ntensify' in North America, Streamlining Nucleic Acid Drug Development
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AGC Biologics Inc.
  • 2. Agilent Technologies, Inc.
  • 3. Ajinomoto Bio-Pharma Services
  • 4. Almac Group Ltd.
  • 5. Biomay AG
  • 6. BioSpring GmbH
  • 7. Catalent, Inc.
  • 8. Charles River Laboratories International, Inc.
  • 9. CordenPharma International GmbH
  • 10. Creative Biogene
  • 11. Danaher Corporation
  • 12. Eurofins Scientific SE
  • 13. Evonik Industries AG
  • 14. GenScript Biotech Corporation
  • 15. Lonza Group Ltd.
  • 16. Polypeptide Group AG
  • 17. Recipharm AB
  • 18. Rentschler Biopharma SE
  • 19. Samsung Biologics
  • 20. The Scripps Research Institute
  • 21. Touchlight Group
  • 22. Univercells Group
  • 23. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. NUCLEIC ACID THERAPEUTICS CDMO MARKET MULTI-CURRENCY
  • FIGURE 2. NUCLEIC ACID THERAPEUTICS CDMO MARKET MULTI-LANGUAGE
  • FIGURE 3. NUCLEIC ACID THERAPEUTICS CDMO MARKET RESEARCH PROCESS
  • FIGURE 4. NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 17. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 19. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. NUCLEIC ACID THERAPEUTICS CDMO MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 25. NUCLEIC ACID THERAPEUTICS CDMO MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NUCLEIC ACID THERAPEUTICS CDMO MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NUCLEIC ACID THERAPEUTICS CDMO MARKET DYNAMICS
  • TABLE 7. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY DNA THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RNA THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PACKAGING & DISTRIBUTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT & OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RARE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 193. NUCLEIC ACID THERAPEUTICS CDMO MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 194. NUCLEIC ACID THERAPEUTICS CDMO MARKET, FPNV POSITIONING MATRIX, 2024